Delay in the progression of low-risk prostate cancer: Rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial

Neil Fleshner, Leonard G. Gomella, Michael S. Cookson, Antonio Finelli, Andrew Evans, Samir S. Taneja, M. Scott Lucia, Eric Wolford, Matthew C. Somerville, Roger Rittmaster

    Research output: Contribution to journalArticlepeer-review

    Fingerprint

    Dive into the research topics of 'Delay in the progression of low-risk prostate cancer: Rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial'. Together they form a unique fingerprint.

    Medicine & Life Sciences